摘要
目的探讨核苷酸切除修复基因家族成员ER-CC1基因在乳腺癌中的表达情况和新辅助化疗对其的影响及临床意义。方法RT-PCR检测56例术前未行治疗的乳腺癌标本和36例术前曾接受新辅助化疗的乳腺癌标本中ERCC1基因的表达。结果未化疗组的乳腺癌中,ERCC1基因阳性表达率为37.5%,其表达水平与患者的年龄(t=0.229,P>0.05)、肿瘤大小(F=0.586,P>0.05)、淋巴结转移(t=0.365,P>0.05)、病理分型(t=0.434,P>0.05)、组织学分级(F=0.820,P>0.05)、ER(t=0.523,P>0.05)、PR(t=0.416,P>0.05)和HER-2(t=0.847,P>0.05)均无明显相关性。新辅助化疗组ERCC1基因的表达水平高于未化疗组,差异有统计学意义(t=3.428,P<0.01)。结论耐药基因ER-CC1的表达不受乳腺癌临床病理特征的影响,但新辅助化疗可能上调ERCC1基因的表达水平,在术后化疗中应予重视。
Objective To investigate the expression and clinical significance of ERCC1 gene, one member of the nucleotide excision repair gene family, in breast cancer before and after neoadjuvant chemotherapy. Methods The expression of ERCC1 gene was detected by reverse transcription polymerase chain reaction （RT-PCR） in 56 specimens of breast cancer patients without any preoperative treatment and 36 tumor tissues of the patients who had been treated by neoadjuvant chemotherapy preoperatively. Results The positive expression rate of ERCC1 gene in breast cancer was 37.5% , and its expression had no relations with patient＇s age （ t = 0. 229,P 〉 0.05 ） , tumor size （ F = 0. 586, P 〉 0.05 ） , axillary lymph node metastasis （ t = 0. 365,P 〉 0.05 ）, pathological type （ t = 0. 434, P 〉 0.05 ）, histological grade （ F = 0. 820, P 〉 0.05 ）, ER （t=0.523,P〉0.05）, PR （t=0.416,P〉0.05）, and HER-2 （t=0.847,P〉0.05）. The expression of ERCC1 gene in turner was higher in neoadjuvant chemotherapy group than in the non-chemotherapy group, and there was a statistically significant difference （ t = 3. 428,P 〈 0.01 ）. Conclusions The expression of ERCC1 gene is not affected by the clinical and pathological features of breast cancer, but may be increased by neoadjuvant chemotherapy, so postoperative neoadjuvant chemotherapy should be given much attention.
出处
《中华乳腺病杂志（电子版）》
CAS
2009年第1期31-34,共4页
Chinese Journal of Breast Disease(Electronic Edition)
基金
深圳市卫生局重点项目(200628)
关键词
乳腺肿瘤
新辅助化疗
核苷酸切除修复
ERCC1
多药耐药基因
Breast neoplasms
Neoadjuvant chemotherapy
Nucleotide excision repair
ERCC1
Muhidrug resistance gene
